Anti-CD47 agent-based treatment of CD20-positive cancer
Methods, kits, and compositions are provided herein that can be used to treat CD20+ cancer using an anti-CD47 agent such as an antibody. The anti-CD47 agent can be used alone or in combination with one or more additional agent such as an anti-CD20 antibody.
1. A method of effectively treating or reducing cancer burden with an overall response rate of at least 40% in human subjects, wherein the human subjects have Non-Hodgkin's lymphoma (NHL) and are refractory to rituximab, comprising:
(a) determining, before administering steps, that the human subjects are refractory to rituximab;
(b) selecting the refractory subjects for treatment;
(c) administering to the refractory subjects for four weeks a first cycle comprising (1) a priming dose of anti-CD47 antibody at about 1 mg of antibody per kg of body weight at time 0 (T0), (2) a dose of at least 30 mg of the anti-CD47 antibody per kg of body weight once every week beginning one week after TO, and (3) a dose of 375 mg/m 2 of anti-CD20 antibody once every week; and
(d) administering to the refractory subjects for four weeks a second cycle comprising (1) a dose of at least 30 mg of the anti-CD47 antibody per kg of body weight once every two weeks, and (2) a dose of 375 mg/m 2 of the anti-CD20 antibody once every four weeks;
thereby effectively treating or reducing cancer burden in the refractory subjects such that an overall response rate (ORR) of at least 40% is achieved.
2. The method of claim 1 , wherein the NHL is indolent lymphoma, follicular lymphoma (FL), or diffuse large B cell lymphoma (DLBCL).
3. The method of claim 1 , wherein the human subjects are relapsed or refractory to at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or greater than 10 prior lines of cancer therapy.
4. The method of claim 1 , wherein the anti-CD47 antibody comprises or consists of Hu5F9-G4.
5. The method of claim 1 , wherein the anti-CD20 antibody comprises an Fc capable of at least one of ADCC and ADCP.
6. The method of claim 1 , wherein the anti-CD20 antibody comprises or consists of rituximab.
7. The method of claim 1 , wherein the first cycle further comprises a loading dose of at least 30 mg/kg on Day 11 (week 2).
8. The method of claim 1 , wherein the second cycle is repeated as one or more additional cycles without limit or until a clinical benefit is reduced or lost.
9. The method of claim 1 , wherein the human subjects are subjects having DLBCL.
10. The method of claim 1 , wherein the human subjects are subjects having indolent lymphoma.
11. The method of claim 10 , wherein the human subjects are subjects having FL.
12. The method of claim 1 , comprising repeating steps (c) and (d) multiple times, wherein when steps (c) and (d) have been repeated 3 times, the anti-CD20 antibody is administered to the human subjects at a dose of 375 mg/m 2 once every eight weeks.
13. The method of claim 1 , wherein the anti-CD47 antibody and the anti-CD20 antibody are administered to the human subjects until the subjects lose a clinical benefit.
14. The method of claim 1 , wherein the anti-CD47 antibody is Hu5F9-G4 and the anti-CD20 antibody is rituximab.
15. The method of claim 1 , wherein the cancer has been classified as CD20 + based on histopathology, flow cytometry, molecular classification, or a combination thereof.
16. The method of claim 1 , wherein the anti-CD47 antibody is Hu5F9-G4, which has the heavy chain sequence set forth in SEQ ID NO: 1 and the light chain sequence set forth in SEQ ID NO: 2.
17. The method of claim 1 , wherein the anti-CD47 antibody and the anti-CD20 antibody are administered concurrently.
18. The method of claim 1 , wherein the anti-CD47 antibody and the anti-CD20 antibody are administered sequentially.
19. The method of claim 1 , wherein the anti-CD47 antibody is administered intravenously.
20. The method of claim 1 , wherein the anti-CD20 antibody is administered intravenously.